Clinical Trial Update: CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study [Phase 2]

View source ↗

Summary

Multicentre Phase II trial comparing CHOP versus GEM-P as first-line therapy for various peripheral T-cell lymphomas; current study status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Anaplastic Large Cell Lymphoma Alk-negative
• Angioimmunoblastic T-cell Lymphoma
• Enteropathy-associated T-cell Lymphoma
• Hepatosplenic Gamma-delta T-cell Lymphoma
• Peripheral T-cell Lymphoma Not Otherwise Specified

Drugs mentioned

• CISPLATIN (cisplatin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Gemcitabine (Gemcitabine)
• PREDNISONE (Prednisone)
• Vincristine (vincristine)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Peripheral T-cell Lymphoma NOS, Anaplastic Large Cell Lymphoma, ALK-Negative | Phase 2 | Status: UNKNOWN